Genetic sequencing price tag plunging

Genetic sequencing costs are dropping at an accelerated velocity, The New York Times reports, in an article that predicts that their increased affordability will finally bring personalized medicine into everyday medical care. Driving the cost drop: Improvements in semiconductor manufacturing that have drastically boosted processing power and transistor density, the article points out. Others have predicted in the past that gene sequencing would become cheaper and help personalized medicine blossom with all kinds of custom treatments for diseases like cancer. While that has not happened yet, this time is different, predicts industry people like Clifford Reid, co-founder, president and chairman of Complete Genomics. The story cites his prediction from the company website that genomic sequencing is on its way to becoming as affordable as a blood test. Place your bets now as to if and when that will come to pass. Story

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.